Is European Heart Journal a Good Journal? The ESC Flagship, Decoded
European Heart Journal is the ESC flagship for cardiology. Here's when your paper fits, what editors prioritize, and how it compares to Circulation, JACC, and JAMA Cardiology.
Journal fit
See whether this paper looks realistic for European Heart Journal.
Run the Free Readiness Scan with European Heart Journal as your target journal and see whether this paper looks like a realistic submission.
European Heart Journal at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- European Heart Journal's scope and readership determine whether the journal is a useful target.
- Scope specificity matters more than headline metrics for most manuscript decisions.
- Acceptance rate of ~10% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope, borderline fit rarely improves after submission.
- If timeline matters: European Heart Journal takes ~20 days. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
How to read European Heart Journal as a target
This page should help you decide whether European Heart Journal belongs on the shortlist, not just whether it sounds impressive.
Question | Quick read |
|---|---|
Best for | European Heart Journal is the European Society of Cardiology's flagship publication and one of the world's. |
Editors prioritize | European scope with global relevance |
Think twice if | Small single-center studies without broader relevance |
Typical article types | Clinical Research, Basic Science, Rapid Communication |
Quick answer: European Heart Journal (JIF 45.3, 2026 JCR release) is the highest-impact cardiology journal in the world and the flagship of the European Society of Cardiology. It is a strong journal for papers with broad cardiovascular consequence and real ESC-level implementation value. It is a weak journal for elegant mechanism papers that lack a clinical bridge.
The Editorial Distinction
EHJ editors care about one thing above all: does this paper change how cardiologists think or act at population scale?
Big numbers matter more than elegant mechanisms here. A 50,000-patient registry showing that a common practice is harmful will beat a beautifully executed bench study every time. ESC guidelines are published in EHJ, and the journal's editorial gravity orbits around that function. If your paper could plausibly inform the next ESC guideline update, you are in the right place. If editors would need to imagine a long chain of translational steps before the paper matters clinically, you are not.
The Numbers
Metric | Value |
|---|---|
2025 Journal Impact Factor (2026 JCR release) | 45.3 |
5-Year IF | ~42.2 |
Publisher | Oxford University Press (for ESC) |
Quartile | Q1 in Cardiac and Cardiovascular Systems |
Acceptance rate | ~8-12% |
APC | Free (subscription) with OA option |
Scope | Clinical, translational, epidemiological cardiovascular research |
How European Heart Journal Compares
Journal | IF (2024) | Society | Best For |
|---|---|---|---|
European Heart Journal | 45.3 | ESC | Guideline-relevant, large-scale cardiovascular evidence |
Circulation | 41.3 | AHA | Broad cardiovascular science including mechanistic |
JACC | 22.3 | ACC | Practice-facing clinical cardiology |
JAMA Cardiology | 15.2 | AMA | Concise clinical cardiology, fast editorial decisions |
EHJ vs Circulation: The two highest-impact cardiology journals serve different editorial cultures. EHJ leans ESC, which means European epidemiological data, prevention, and guideline-network thinking carry natural weight. Circulation leans AHA, which gives more room for mechanistic cardiovascular science alongside clinical evidence. A US-based randomized trial could go to either, but Circulation is often the more natural home for American cardiology. For ESC-aligned prevention, imaging, or heart failure registries, EHJ is the default.
EHJ vs JACC: JACC JIF 22.3 is the ACC flagship and publishes excellent clinical cardiology, but the gap in JIF is substantial. If the paper is strong enough for EHJ, the question is usually whether the ESC-level implementation story is convincing. If it isn't, JACC is not a downgrade for practice-relevant work.
EHJ vs JAMA Cardiology: JAMA Cardiology JIF 15.2 offers faster editorial turnaround, tighter word limits, and JAMA's disciplined reporting style. For concise clinical studies that don't need ESC-flagship scope, JAMA Cardiology can be the smarter first move.
Submit If
- The paper has broad cardiovascular consequence visible from the first page
- The study could plausibly inform ESC guidelines, clinical practice, or prevention strategy
- The evidence package is large, complete, and stands on its own without generous interpretation
- European or global epidemiological context strengthens the story
Journal fit
See whether this paper looks realistic for European Heart Journal.
Run the scan with European Heart Journal as the target. Get a manuscript-specific fit signal before you commit.
Think Twice If
- The paper is mechanistically elegant but clinically distant, Circulation or a basic-science journal may fit better
- The real audience is one cardiology subspecialty, not the broad ESC readership
- The sample size or effect size doesn't justify a top-cardiology claim
- You're choosing EHJ for the JIF rather than because the paper genuinely belongs in the ESC ecosystem
Common decision questions
Is European authorship required?
No. EHJ publishes globally. But the journal's editorial identity is ESC-centered, which means papers with European registry data, ESC-aligned clinical questions, or prevention-focused epidemiology have a natural advantage. A strong trial from any country with clear cardiovascular consequence will be considered on merit.
How long does review take?
First decisions typically come within 3-6 weeks. EHJ has a fast-track option for major clinical trials. Rejection rates are high at the editorial screen stage, so many authors receive desk rejections within 1-2 weeks.
Is EHJ open access?
EHJ is primarily subscription-based but offers an OA option. Most authors publish under the subscription model at no cost. OA fees are substantial if you choose that route.
What about the JACC family journals as alternatives?
JACC has an expanding family (JACC: Heart Failure, JACC: CardioOncology, JACC: Imaging, etc.) that provides good specialist alternatives. If your paper is subspecialty-focused, a JACC family journal may provide better audience alignment than trying for EHJ's broad readership.
Before submitting, a EHJ scope and readiness check can help you assess whether the cardiovascular consequence is broad enough for EHJ or better positioned for Circulation, JACC, or a subspecialty cardiology journal.
Before you submit
Most EHJ desk rejections turn on framing rather than data quality. If the broad cardiovascular consequence is not visible on the first page, an editor reading dozens of submissions a week may not work to find it. The fixable problems are usually the same ones: a clinical bridge that is implied rather than stated, a sample that is large but framed for a single subspecialty, or an abstract that leads with method instead of population-level impact.
A EHJ submission readiness check identifies the specific framing and scope issues that trigger desk rejection before you submit.
The ESC flagship editorial model
European Heart Journal (IF ~45.3, OUP/ESC) is the flagship of the European Society of Cardiology. The editorial model requires European or global cardiovascular relevance, work that "can travel across healthcare systems and ESC readerships." Single-center studies must justify broader applicability.
EHJ does not accept papers without cardiovascular relevance beyond one subspecialty. The journal also requires AI disclosure in cover letters and offers Fast Track review for time-sensitive findings. It uses open peer review through the ESC editorial process.
The cascade: EHJ -> EHJ Open (~$2,500 OA) -> Europace / EHJ-Cardiovascular Imaging / EHJ-Quality of Care.
A EHJ desk-rejection risk check scores fit against the journal's editorial bar.
Why timing your submission matters
Journal editorial capacity fluctuates. Submissions during major conference seasons face longer reviewer turnaround. End-of-year submissions may sit longer during holiday periods. New IF announcements (June each year) can temporarily increase submissions to journals whose IF rose.
For selective journals, the practical advice is: submit when the manuscript is ready, not when the calendar seems favorable. A paper that is scientifically complete and properly targeted will succeed regardless of timing. A paper with gaps will fail regardless of when you submit.
A EHJ submission readiness check evaluates fit independently of timing.
How to use this information strategically
The practical move is to decide EHJ versus its nearest neighbors before you write the cover letter, not after a desk rejection. If the work is ESC-aligned prevention, imaging, or a registry with European context, EHJ is the natural default. If it is mechanistic cardiovascular science, Circulation is often the better first home. If it is concise and practice-facing, JAMA Cardiology trades scope for a faster decision. Matching the paper to the right culture up front saves a rejection cycle.
A EHJ scope and readiness check gives you the verdict: does your paper fit this journal?
Frequently asked questions
European Heart Journal has a 2025 Journal Impact Factor of 45.3, the highest of any cardiology journal. It outranks Circulation JIF 41.3, JACC JIF 22.3, and JAMA Cardiology JIF 15.2. EHJ is Q1 in Cardiac and Cardiovascular Systems.
Both are extremely selective (acceptance rates around 8-12%), but they reward different things. EHJ leans toward ESC guideline-relevant work with European epidemiological context. Circulation, the AHA flagship, leans toward broad mechanistic cardiovascular science and US-centered clinical trials. Neither is objectively easier.
European authorship helps with some study types (registries, guideline-relevant epidemiology), but EHJ is a global journal. What matters more than geography is whether the paper has ESC-level implementation relevance. Major trials from any country get published if the cardiovascular consequence is broad enough.
EHJ publishes large clinical trials, ESC guideline updates, registries, meta-analyses, cardiovascular prevention and imaging studies, and selected translational work. The common thread is broad cardiovascular consequence with visible clinical or policy implications. Narrow mechanistic studies without a clinical bridge are a weak fit.
Sources
- European Heart Journal homepage, Oxford University Press.
- EHJ author guidelines, Oxford University Press.
- Clarivate Journal Citation Reports (2026 JCR release for the 2025 Journal Impact Factor).
Final step
See whether this paper fits European Heart Journal.
Run the Free Readiness Scan with European Heart Journal as your target journal and get a manuscript-specific fit signal before you commit.
Target journal carried over: European Heart Journal
Anthropic Privacy Partner. Your manuscript is never used to train any model.
Where to go next
Start here
Same journal, next question
- EHJ Submit Guide: European Heart Journal Requirements
- How to Avoid Desk Rejection at European Heart Journal (2026)
- European Heart Journal Review Time: What Authors Can Actually Expect
- European Heart Journal Acceptance Rate: What Authors Can Use
- European Heart Journal Impact Factor 2026: 45.3, Q1, Rank 2/237
- Is Your Paper Ready for European Heart Journal? The ESC's Flagship Standard